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Hepatocellular carcinoma is the third leading cause of cancer-related death in the world, and cirrhosis is the main cause
of hepatocellular carcinoma and adversely affects surgical outcomes. Liver resection, liver transplantation, and local
ablation are potentially curative therapies for early hepatocellular carcinoma (HCC). There exists an obvious histological
variability of severity within cirrhosis which has different clinical stages. For patients with Child-Pugh B cirrhosis and/or
portal hypertension and HCC within Milan criteria, consensus guidelines suggest that liver transplantation is the best
treatment of choice; liver resection is widely accepted as first-line treatment for patients with early-stage HCC and
preserved liver function; and local ablation is the treatment of choice in patients with small tumors who are not
candidates for surgery or can be used as a temporary treatment during the waiting period for transplantation. For
patients with compensated cirrhosis or Child A cirrhosis, the selection of surgical modality based on subclassification of
cirrhosis remains unclear. This review examines the current status of the selection of surgical modality for hepatocellular
carcinoma treatment in cirrhotic patients and aims to emphasize the effects of the severity of cirrhosis on the selection
of surgical modality for the treatment of hepatocellular carcinoma.
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Introduction
Hepatocellular carcinoma (HCC) is the third leading
cause of cancer-related deaths worldwide and primarily
arises from cirrhosis [1,2]. The reported overall inci-
dence of HCC in patients with cirrhosis is 3.4% to 5.6%
[3,4], and the annual incidence of HCC is 1.7% to 3.7%
in Western populations [5]. Some studies have demon-
strated that subclassifications of cirrhosis are closely re-
lated to the incidence of HCC [6,7]. It has been reported
that 60% to 90% of HCC patients have associated under-
lying cirrhosis [5,8]. Therefore, cirrhosis is an important
factor that cannot be ignored in the surgical treatment
of HCC.
According to the guidelines of the American Associ-
ation for the Study of Liver Diseases (AASLD) and the
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unless otherwise stated.for safe liver resection (LR) include a Child-Pugh A clas-
sification, the absence of portal hypertension and normal
serum bilirubin [9]. However, these guidelines do not
emphasize the importance of underlying cirrhosis. For
the majority of HCC patients, obvious histological vari-
ability in the severity of the so-called one-stage cirrhosis
exists. For compensated cirrhosis or Child-Pugh A cir-
rhosis, there are also some advanced cirrhosis (for ex-
ample, F4B-F4C using Laennec scoring system) which is
dangerous for resection; therefore, it is important to
recognize these differences to make proper surgical deci-
sions in clinical practice [10]. LR, liver transplantation
(LT), and local ablation (LA) are considered to be cura-
tive treatments for early HCC patients and offer the best
long-term outcomes [11,12]. LT is widely accepted as
the optimal treatment for patients with underlying cir-
rhosis and HCC that fulfills the Milan criteria because it
can eliminate both tumors and the cirrhotic liver [13].
However, due to organ shortages, high costs, and tumor
progression during the waiting period, the application of
LT is largely limited [14,15]. LR remains the mainstayThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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survival that is comparable to that of LT [16-18] and is
also applicable for lesions not indicated for LT. How-
ever, the remnant liver with underlying cirrhosis is
prone to multicentric de novo carcinogenesis after LR,
and the long-term outcomes of such HCC patients
undergoing LR were significantly worsened by increased
severity of cirrhosis [19,20]. Therefore, the severity of
cirrhosis might play a key role in determining whether
LR or LT is the most appropriate modality for the treat-
ment of early HCC in these cirrhotic patients. Over re-
cent decades, LA has shown satisfactory long-term
outcomes when applied to cases with early HCC. LA is
accepted as the first-line treatment for HCCs ≤3 cm in
diameter in the current guidelines [21,22]. Increasingly,
the question of whether the ablation of small tumors
(HCC ≤3 cm) can provide long-term outcomes that are
comparable to those of resection when the severity of
cirrhosis is considered has been raised. Therefore, un-
derstanding the potential outcomes of LT, LR, or LA
based on the severity of cirrhosis is essential for the
individualization of surgical modalities. This review
aims to examine the current status of the selection of
surgical modality for HCC.
Cirrhosis and long-term outcomes of LR
With improvements in surgical techniques, evaluations
of liver function, and perioperative care, the long-term
outcomes of LR for HCC have greatly improved in re-
cent decades. Unfortunately, the long-term outcomes
of LR remain unsatisfactory largely because of the high
incidence of postoperative recurrence. Tumor recur-
rence can result from the spread of HCC cells into the
remnant liver via the portal vein before or during LR
or new foci due to coexisting cirrhosis and other HCC-
relevant risk factors [5,23-25]. Some studies have indi-
cated that the long-term outcomes of HCC patients
with cirrhosis are significantly worse than those with-
out cirrhosis after LR [20,25-29]. The 5-year overall
survival (OS) rate after LR for HCC in patients with
advanced cirrhosis is less than 30%, whereas this rate is
more than 50% in those without cirrhosis [20,30,31].
Taura and colleagues [20] compared the long-term
outcomes of 127 HCC patients without cirrhosis with
those of 129 patients with Child A cirrhosis and 37
with Child B cirrhosis according to the oncological
Milan criteria. These authors found that the 5-year OS
and recurrence rates were 81% and 54% in the patients
without cirrhosis, 54% and 78% in the Child A cirrhosis
patients, and 28% and 91% in the Child B cirrhosis pa-
tients, respectively. These results indicate that coexist-
ing cirrhosis is associated with higher recurrence rates
and lower OS rates. Several subsequent studies also re-
vealed that the severity of fibrosis is strongly associatedwith 5-year survival, which is significantly worsened by
increased liver fibrosis severity [26,32]. In recent de-
cades, cirrhosis has only been considered as a ‘present’
or ‘absent’ variable in surgical studies of HCC, and the
subclassification of cirrhosis has not been emphasized.
In our previous study, cirrhosis was classified into
mild, moderate, and severe based on the morphological
changes of the liver as evaluated during surgery. The
3-year OS rates of the HCC patients with mild, moder-
ate, and severe cirrhosis after LR were 74.3%, 48.1%,
and 26.7%, respectively (P = 0.001). The OS rate was
significantly worse in patients with severe cirrhosis
than in those with mild cirrhosis [33]. A recent study
conducted by Kim [19] revealed that the cumulative
recurrence rates significantly increase with increased
cirrhosis staging as evaluated by the Laennec staging
system. In this study, the 3-year cumulative recurrence
rates in patients with no cirrhosis, stage 4A cirrhosis,
stage 4B cirrhosis, and stage 4C cirrhosis were 21.8%,
42.9%, 68.5%, and 86.7%, respectively (P < 0.001).
Therefore, the recognition of the presence of varying
underlying severity of fibrosis and cirrhosis is critically
important in determining the long-term outcomes of
LR (Table 1). The Laennec system is based on liver bi-
opsies and was modified from the METAVIR system.
This system has been well established for the staging of
the severity of cirrhosis and is widely accepted in stud-
ies of chronic liver diseases. The potential application
of this system in surgical settings deserves further
study, particularly regarding the evaluation of the ef-
fects of cirrhotic severity on long-term outcomes of LR.
LR or LT?
Both LR and LT have been proposed as the first-line
treatment for early HCC. No waiting time is required
prior to LR; thus, the dropout and tumor progression
which are associated with the waiting time for LT are
avoided. However, LT can eliminate both tumors and
the cirrhotic liver, which is prone to de novo occur-
rences of HCC. Therefore, whether LR or LT is the
most appropriate modality for the treatment of early
HCC remains controversial. Some studies have indi-
cated that, for HCCs that fulfill the Milan criteria in
cirrhotic livers, the long-term outcomes of LT are bet-
ter than those of LR because both the tumor and the
underlying cirrhotic liver are removed [34-36]. Sapiso-
chin and colleagues reported that the 10-year OS rate
was 49% among a group of LT patients and that this
rate was 33% in an LR group. In this study, the 10-year
recurrence rates were 20% and 83% for LT and LR, re-
spectively (P < 0.01) [34]. However, other studies have
suggested that LR can achieve 5-year OS rates that are
similar to those of LT [16,37-39]. Two meta-analyses
compared the long-term outcomes of LT and LR for
Table 1 Long-term outcomes of LR in recent studies with










Non-cirrhosis 127 81 <0.001
Child A cirrhosis 129 54
Child B cirrhosis 37 28
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Moderate cirrhosis 29 48.1
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38 84 NS
Cirrhosis (METAVIR 4) 89 63
Wang et al.
[26]
Fibrosis (Ishak 1 to 5) 135 73 0.01









The overall survivals indicate the 5-year overall survival rates, except § which
indicates the 3-year overall survival rate. PH, portal hypertension; NS,
not significant.
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posing conclusions [40,41]. Notably, tumor progression
and dropout during the waiting period might artificially
improve the long-term outcomes of LT. Intent-to-treat
(ITT) analysis, which accounts for tumor progression
and dropout among potential LT patients, has been pro-
posed for comparing survival between LT and LR.
Koniaris compared the long-term outcomes of LR with
those of LT using an ITT analysis and found that the 5-
year OS rates were not significantly different between
LR and LT for HCC patients who fulfilled the transplant-
ation criteria, but for patients with MELD scores <10, the
5-year OS was better after LR than after LT [17]. Add-
itionally, the patients who undergo LT in this study have
more advanced cirrhosis, including Child B liver function
and portal hypertension; the characteristics of which are
not always indications for LR, and this might have beenanother reason for this discrepancy [41]. However, ad-
vanced cirrhosis was defined functionally and not histo-
logically in those studies. For patients with histologically
severe cirrhosis and Child A liver function, it remains un-
clear whether LR or LT should be performed. Using the
Laennec staging system in which the cirrhosis of Child A
patients is divided into mild (F4A), moderate (F4B), and
severe (F4C), we retrospectively studied the long-term
outcomes of LR and LT in early HCC patients with vary-
ing degrees of cirrhosis. Our unpublished data suggest
that LR achieved long-term outcomes that were compar-
able to those of LT in patients with single HCCs of ≤5 cm
in non-cirrhotic or mildly cirrhotic backgrounds, but the
LR patients achieved worse outcomes when moderate or
severe cirrhotic backgrounds were present. Our prelimin-
ary data suggest that LR should remain the first choice for
early HCC patients with Child A, mild or no cirrhosis,
and that LT should be recommended for those patients
with moderate or severe cirrhosis.
LR or RFA?
LR and radiofrequency ablation (RFA) are alternatives
to LT for the treatment of early HCC, and whether RFA
or LR is the better treatment option has been debated in
recent years. Three recent randomized controlled trials
(RCTs) compared the long-term outcomes of LR with
those of RFA in early HCC patients and arrived at
significantly different conclusions. One of these trials
reported that LR produced better survival and lower re-
currence rates than RFA among patients with HCCs
that fulfilled the Milan criteria and that the 5-year OS
rates following LR and RFA were 75.7% and 54.8%, re-
spectively (P < 0.05) [42]. However, the other two RCTs
reported that the long-term outcomes were comparable
between the LR and RFA groups for HCCs of 4 to 5 cm
and that the 5-year OS rates for both treatments
approached 60% to 70% [43,44]. Several retrospective
studies have reported that RFA can achieve long-term
outcomes that are comparable to those of LR in the
treatment of single HCCs of ≤3 cm in patients with
cirrhosis [45,46]. Peng and colleagues [47] recently that
the efficacy and safety of RFA were better than those of
LR among patients with single HCCs ≤2 cm. Particularly
in patients with central HCCs (that is, tumors located at
least 3 cm away from the liver capsule), the OS and
disease-free survival rates were significantly better in
the RFA group than in the LR group [48]. Taken to-
gether, these results suggest that several factors might
account for these discrepancies. First, in the percutan-
eous RFA procedure, the treatment of tumors that are
larger than a single ablative area required repeated abla-
tions. It is difficult to overlay every ablative area pre-
cisely in the three-dimensional liver with the guidance of
two-dimensional ultrasonography [42]. Furthermore,
Table 2 Comparative studies of survival following AR












AR 156 32.1 66.0 0.01
NAR 54 57.4 35.0
Kaibori
et al. [65]
AR 34 29.4 53.7 0.717
NAR 213 54.0 52.5
Wakai
et al. [61]
AR 95 46.3 67.0 0.036
NAR 63 66.7 59.0
Yamashita et
al. [64]
AR 201 48.8 76.0 NS
NAR 120 68.3 74.0
Ueno
et al. [67]
AR 52 51.9 63.0 0.19
NAR 64 67.2 58.0
Eguchi
et al. [60]
AR 2267 NA 65.5 0.053
NAR 3514 NA 62.4
Tanaka
et al. [66]
AR 83 38.6 54.0 0.34
NAR 42 52.4 61.0
Nanashima
et al. [68]
AR 49 38.8 55.0 NS
NAR 64 42.2 66.0
Kamiyama
et al. [63]
AR 152 23.7 83.0 <0.001
NAR 133 47.4 65.3
Kang
et al. [69]
AR 146 54.8 48.0 0.762
NAR 21 76.2 40.0
AR, anatomic resection; NAR, non-anatomic resection; NA, not available;
NS, not significant.
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related to underlying liver cirrhosis [20,25,26,49]. Patients
undergoing RFA are often cirrhotic or have Child B cir-
rhosis and are thus typically not good candidates for LR
due to the sacrifice of additional normal liver tissue and
blood loss, which can induce a greater number of compli-
cations and negatively affect treatment outcome [50].
Tumor size and underlying cirrhosis obviously play im-
portant roles in determining the treatment outcomes.
Many guidelines for the treatment of HCC recommend LR
and RFA as alternatives for patients with good liver func-
tion, HCCs ≤3 cm and no more than three nodules
[12,51,52]. The severity of cirrhosis, tumor sizes, tumor lo-
cations, and technical factors should be considered when
selecting surgical modalities. For patients with HCCs
≤3 cm, deep tumor locations, and moderate or severe cir-
rhosis, RFA is a better choice of treatment [12,52-54] be-
cause it preserves more liver parenchyma and has a lower
risk of postoperative complications [55]. Due to the ad-
verse effects of cirrhosis on the long-term outcomes of
HCC, LT is still considered to be the best treatment strat-
egy for patients with moderate or severe cirrhosis if the
transplantation criteria are met. RFA can be used as a tem-
porary treatment during the waiting period for LT [54]. For
patients with HCCs ≤3 cm without cirrhosis or with mild
cirrhosis, RFA and LR can both be valid treatment choices
depending on tumor location and technical feasibility.
Anatomic resection or non-anatomic resection?
LR includes anatomic resection (AR) and non-anatomic
resection (NAR). AR is defined as the systematic re-
moval of a hepatic segment confined by tumor-bearing
portal tributaries in accordance with Couinaud’s system,
whereas NAR is defined as the removal of the tumor
with an adequate margin irrespective of the segments.
Debate remains regarding whether AR or NAR should
be performed for HCC. Most recurrences that occur in
the remnant liver originate from the primary tumor via
microscopic vascular invasion and peripheral spread
along the portal venous tributaries, which are the most
commonly reported risk factors that are associated with
poor prognoses [56-58]. Therefore, AR is advocated for
HCC treatment to eradicate both the tumors and poten-
tial microscopic metastases. Some studies have indi-
cated that the long-term outcomes of AR groups are
significantly better than those of NAR groups [59-63].
In contrast, other studies have failed to demonstrate the
survival benefits of AR [64-69]. These investigators pre-
ferred to perform NAR to preserve larger volumes of
functional liver parenchyma in patients with cirrhosis
and limited hepatic functional reserves. This preserva-
tion decreases the incidence of postoperative liver fail-
ure and thus improves long-term outcomes suggesting
that the removal of the tumor and the preservation ofthe liver parenchyma are equally important in such
patients. Notably, the major causes of death in these
studies included not only recurrence but also progres-
sive liver insufficiency due to advanced cirrhosis be-
cause regeneration was impaired, and the normalization
of liver function was slow or did not occur at all. Two
recent meta-analyses of observational studies compared
the long-term outcomes of AR and NAR and reported
conflicting results [70,71]. Notably, the assessed studies
were not all RCTs, and underlying cirrhosis was more
common in the NAR patients who exhibited more ad-
vanced liver dysfunction than did the AR patients [54].
A meta-regression approach was utilized to explain this
inconsistency [72]. The clearest difference between the
patients who underwent AR and NAR was the differen-
tial prevalence of cirrhosis as shown in Table 2. This dif-
ference indicated a potential selection bias that would
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patients who underwent AR to appear superior to those
of the patients who underwent NAR because the poorer
liver function reserve of the latter group significantly af-
fected the prognoses [72]. Theoretically, AR can remove
the entire portal venous drainage of the involved seg-
ment and provide optimal operative clearance; however,
the severity of cirrhosis might play a more important
role than the type of resection in long-term survival of
HCC, and preservation of the liver parenchyma in
patients with cirrhosis should be prioritized over major
resection [73]. Some other researchers have recom-
mended that AR should be performed for HCC in pa-
tients without cirrhosis and that NAR has proven its
long-term efficacy for the treatment of HCC patients
with cirrhosis [64,65]. The optimal resection for each
patient should be chosen based on liver function, liver
functional reserve, and the severity of cirrhosis. For
HCC patients with moderate or severe cirrhosis, LT
should be the first choice if the tumors fulfill LT criteria.
For those tumors that do not meet the LT criteria but
are technically resectable, NAR might be an alternative
treatment modality. AR should be recommended for
HCC patients without cirrhosis or with mild cirrhosis.
Conclusions
Most cases of HCC are associated with cirrhosis, and
the histological severity of cirrhosis varies widely among
patients with Child A liver function. The histological se-
verity of cirrhosis is an important adverse factor that af-
fects the long-term outcomes of LR. It is important to
recognize that the presence of underlying cirrhosis is
critically important for the determination of treatment
options. Therefore, further studies of the effects of the
histological severity of cirrhosis on the long-term out-
comes of surgical modalities are needed to achieve the
best surgical outcomes for HCC patients.
Several issues remain to be resolved. First, although the
histological severity of cirrhosis can be accurately evalu-
ated by liver biopsy, this invasive procedure might cause
new morbidities in patients with liver-diseased patients. A
non-invasive method based on imaging technology needs
to be developed for the staging of the severity of cirrhosis.
Second, a greater number of well-designed RCTs are
needed to confirm the value of incorporating the histo-
logical severity of cirrhosis into the selection of the appro-
priate surgical modality for the treatment of HCC.
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